U.S. Physical Therapy, Inc. (NYSE:USPH) CFO Sells $49,665.00 in Stock

U.S. Physical Therapy, Inc. (NYSE:USPH) CFO Carey P. Hendrickson sold 516 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $96.25, for a total value of $49,665.00. Following the completion of the sale, the chief financial officer now owns 20,469 shares in the company, valued at $1,970,141.25. This represents a 2.46 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

U.S. Physical Therapy Trading Down 0.2 %

Shares of NYSE:USPH opened at $96.27 on Wednesday. The company has a market capitalization of $1.45 billion, a P/E ratio of 102.41, a P/E/G ratio of 4.34 and a beta of 1.46. U.S. Physical Therapy, Inc. has a 1 year low of $76.18 and a 1 year high of $113.63. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.78 and a quick ratio of 1.78. The business’s 50 day simple moving average is $88.54 and its 200 day simple moving average is $90.03.

U.S. Physical Therapy Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, December 6th. Investors of record on Friday, November 15th were given a dividend of $0.44 per share. This represents a $1.76 dividend on an annualized basis and a yield of 1.83%. The ex-dividend date of this dividend was Friday, November 15th. U.S. Physical Therapy’s dividend payout ratio is currently 187.23%.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. StockNews.com upgraded U.S. Physical Therapy from a “sell” rating to a “hold” rating in a research note on Wednesday, August 21st. Barrington Research reiterated an “outperform” rating and set a $108.00 target price on shares of U.S. Physical Therapy in a research note on Thursday, November 21st. JPMorgan Chase & Co. increased their target price on U.S. Physical Therapy from $117.00 to $120.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 3rd. Finally, Bank of America reiterated a “neutral” rating and set a $90.00 target price (down previously from $114.00) on shares of U.S. Physical Therapy in a research note on Monday, October 7th.

Institutional Investors Weigh In On U.S. Physical Therapy

A number of large investors have recently added to or reduced their stakes in the stock. State Street Corp grew its position in U.S. Physical Therapy by 17.5% during the third quarter. State Street Corp now owns 667,868 shares of the company’s stock worth $56,522,000 after buying an additional 99,244 shares in the last quarter. Southernsun Asset Management LLC boosted its holdings in shares of U.S. Physical Therapy by 10.5% in the 3rd quarter. Southernsun Asset Management LLC now owns 547,111 shares of the company’s stock valued at $46,302,000 after purchasing an additional 52,062 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of U.S. Physical Therapy by 2.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 423,846 shares of the company’s stock valued at $39,173,000 after purchasing an additional 10,462 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of U.S. Physical Therapy by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 343,073 shares of the company’s stock valued at $29,040,000 after purchasing an additional 4,477 shares in the last quarter. Finally, Envestnet Asset Management Inc. boosted its holdings in shares of U.S. Physical Therapy by 4.1% in the 2nd quarter. Envestnet Asset Management Inc. now owns 239,982 shares of the company’s stock valued at $22,179,000 after purchasing an additional 9,434 shares in the last quarter.

U.S. Physical Therapy Company Profile

U.S. Physical Therapy, Inc operates outpatient physical therapy clinics. The company operates through Physical Therapy Operations and Industrial Injury Prevention Services segments. The company provides pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries.